Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003464661 | SCV004205707 | likely pathogenic | Tyrosinemia type II | 2023-10-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003464661 | SCV004297026 | pathogenic | Tyrosinemia type II | 2023-12-25 | criteria provided, single submitter | clinical testing | This sequence change affects codon 408 of the TAT mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the TAT protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with tyrosinemia (PMID: 16917729; Invitae). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 11, but is expected to preserve the integrity of the reading-frame (PMID: 16917729). For these reasons, this variant has been classified as Pathogenic. |